Similarly, anti-cancer drugs targeting ADP-ribose polymerase inhibitor (PARPi) can activate the cGAS-STING pathway by inducing cytosolic micronuclei, promoting the secretion of chemokines, such as CCL5, through IFN-γ-induced PD-L1 expression on the tumor cell surface, and the combination of PARP and PD-L1 monoclonal antibody significantly improves the prognosis of patients (5). The gene discussed is CCL5; the disease is neoplasm.